ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On October 12, 2017, AcelRx Pharmaceuticals, Inc. (the “Company” or “AcelRx”) issued a press release that disclosed that the Company’s estimated cash balance as of September 30, 2017 was $67.9 million. The aforementioned financial information is included in the press release, as furnished in Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Item .01Other Events.
On October 12, 2017, the Company issued a press release entitled “AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA,” a copy of which is attached as Exhibit 99.1 to this Report.
Item 2.02Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated October 12, 2017 |
ACELRX PHARMACEUTICALS INC ExhibitEX-99.1 2 ex_96542.htm EXHIBIT 99.1 ex_96542.htm Exhibit 99.1 Press Release AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA REDWOOD CITY,…To view the full exhibit click here
About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
